ArticleCancer medicine2025
Anti-Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin-1 Pathway.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer.Journal of clinical medicine · 2026Review
- Integrated Computational Modeling Reveals a Structurally Plausible Transient Paclitaxel-NK2R Interaction.Bioengineering (Basel, Switzerland) · 2026Article
- A Candidate Small Molecule Targeting Tachykinin Receptor 1 Suppresses Substance P‑Driven Extracellular Signal-Regulated Kinase Activation and Tumor Innervation in Pancreatic Cancer.ACS pharmacology & translational science · 2026Article
- Sorbicillin water fraction from Penicillium flavigenum: Impact on anti-proliferative, apoptotic, and neuroinflammatory responses in glioma model.Molecular biology reports · 2026Article
- Neuron-tumor interplay in colorectal cancer: from mechanisms of onset and progression to targeted therapies.Cell communication and signaling : CCS · 2026Review
- The substance P/ Neurokinin-1 receptor signaling drives perineural invasion in pancreatic ductal adenocarcinoma (PDAC).Frontiers in cell and developmental biology · 2026Article
- Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: Third Edition".International journal of molecular sciences · 2025Article
- Anti-Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin-1 Pathway.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundGlioblastoma (GB) is an aggressive brain tumor characterized by rapid proliferation, invasion, and resistance to therapy. The substance P (SP)/neurokinin-1 receptor (NK-1R) pathway contributes to GB progression by promoting angiogenesis, inflammation, and extracellular matrix remodeling. Aprepitant, an FDA-approved NK-1R antagonist, has shown potential as a therapeutic agent in glioma treatment.
methodsThis study investigates the anti-metastatic effects of aprepitant on U87-MG glioblastoma cells. Cell viability, migration, and invasion were evaluated using WST-1, real-time cell analysis, and Oris migration assays. Gene and protein expression levels were assessed by RT-PCR, ELISA, and microarray analysis.
resultsAprepitant significantly reduced glioma cell proliferation, migration, and invasion in a dose-dependent manner. It downregulated pro-tumorigenic mediators such as VEGF, NF-kB, TNF-α, IL-6, IL-8, CCL3, CXCL3, and TRIM5, indicating suppression of angiogenesis, inflammation, and chemotaxis pathways. DISCUSSION: These findings underscore the potent anti-metastatic and anti-angiogenic effects of NK-1R antagonism in glioblastoma and highlight aprepitant as a promising candidate for future in vivo and in ovo therapeutic investigations targeting extracellular matrix (ECM) remodeling, chemotaxis, and angiogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.